CAU
CSTL icon

Caxton Associates (UK)’s Castle Biosciences CSTL Stock Holding History

Caxton Associates (UK)’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,464
Closed -$874K – 826
2025
Q4 		$874K Buy
+22,464
New +$724K 0.02% 384
2025
Q2 		– Sell
-16,440
Closed -$329K – 723
2025
Q1 		$329K Buy
+16,440
New +$407K 0.01% 601

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caxton Associates (UK)'s CSTL Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 22,464 shares — an estimated $874K sold.

Caxton Associates (UK) first reported a position in CSTL in Q1 2025 and held it in 2 quarters. The position peaked at $874K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 22,464 Castle Biosciences shares in Q1 2026, an estimated $874K.
  • Caxton Associates (UK) first reported a position in Castle Biosciences in Q1 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Castle Biosciences position peaked at $874K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.